|
    OGN U.S.: NYSE

    Organon & Co.

    OGNUS
    After Hours
    Last Updated: Sep 24, 2021 6:44 p.m. EDT Delayed quote

    $ 33.38

    -0.31 -0.92%
    After Hours Volume: 42.9K
    Close Chg Chg %
    $33.69 0.31 0.93%
    Advanced Charting
    Volume: 1.89M 65 Day Avg: 2.39M
    79% vs Avg
    33.00 Day Range 33.95
    27.25 52 Week Range 38.75

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    OGN Overview

    Performance

    5 Day
    • -1.00%
    1 Month
    • -1.64%
    3 Month
    • 11.59%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 6 Full Ratings

    Recent News

    Organon started at buy with $43 stock price target at BofA Securities

    Read full story

    Warren Buffett’s Berkshire Hathaway buys Kroger, cuts stakes in drug makers

    Read full story

    If you’re nervous about the stock market at record highs, consider these five companies that are loved by the smart money

    Read full story

    Merck Spinoff Organon Is Supercheap—and It Just Set a 3.7% Dividend Yield

    Organon stock jumps after earnings beat, initiating dividend with yield well above its peer group

    Read full story

    Plastics Are Still in Demand. This Stock Stands to Profit—but Beware the Risks.

    ObsEva Shares Climb 10% on Licensing Deal With Organon

    ObsEva Shares Buoyed After License Agreement With Organon

    Read full story

    5 Undervalued Healthcare Stocks

    Organon started at neutral with $38 stock price target at J.P. Morgan

    Organon started at outperform at Evercore ISI

    Read full story

    This Former Merck Company Could Have Big Potential

    Organon stock drops 7.8%, Mosaic shares fall 4.2% to lead the S&P 500's losers

    Merck & Co. Spinoff Organon to Join S&P 500

    Chestnut Street Exchange Fund Buys Organon

    on GuruFocus.com

    Bruce Fund Inc Buys IGM Biosciences Inc, Organon, Sells Chevron Corp, MannKind Corp, Prothena ...

    on GuruFocus.com

    Boston Trust Walden Equity Fund Buys AutoZone Inc, TE Connectivity, Intuit Inc, Sells Atmos ...

    on GuruFocus.com

    Boston Trust Walden Funds Buys O'Reilly Automotive Inc, TJX Inc, Ross Stores Inc, Sells Verizon ...

    on GuruFocus.com

    Bny Mellon Stock Index Fund, Inc. Buys Charles River Laboratories International Inc, PTC Inc, ...

    on GuruFocus.com

    Blackrock Funds Buys Organon

    on GuruFocus.com

    Great-west Funds Inc Buys Charles River Laboratories International Inc, PTC Inc, Huntington ...

    on GuruFocus.com

    Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?

    on Motley Fool

    3 Warren Buffett Stocks to Buy in September

    on Motley Fool

    New England Asset Management Inc Buys iShares Select Dividend ETF, Visa Inc, AT&T Inc, ...

    on GuruFocus.com

    Knightsbridge Asset Management, Llc Buys Cars. ...

    on GuruFocus.com

    Top Stocks Warren Buffett Just Bought

    on Motley Fool

    Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates

    on Zacks.com

    Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips

    on Zacks.com

    Merck (MRK) to Report Q2 Earnings: What's in the Cards?

    on Zacks.com

    Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?

    on Motley Fool

    3 Stocks I'd Avoid at All Costs

    on Motley Fool

    Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

    on Motley Fool

    Stay Away From Low-Growth Organon

    on InvestorPlace.com

    Forget Dogecoin: These Dogs of the Dow Are More Likely to Make You Rich

    on Motley Fool

    Organon & Co.

    Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.